Format

Send to

Choose Destination
Oncotarget. 2017 May 9;8(19):31238-31253. doi: 10.18632/oncotarget.16114.

Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.

Author information

1
Departments of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
2
Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI 02903, USA.
3
Department of Nephrology, Shanghai Songjiang District Central Hospital, Shanghai, China.
4
Department of Surgery, Boston University Medical School, Roger Williams Medical Center, Boston University, Providence, RI, 02908, USA.

Abstract

Activation of Src kinase has been implicated in the pathogenesis of acute brain, liver, and lung injury. However, the role of Src in acute kidney injury (AKI) remains unestablished. To address this, we evaluated the effects of Src inhibition on renal dysfunction and pathological changes in a murine model of AKI induced by ischemia/reperfusion (I/R). I/R injury to the kidney resulted in increased Src phosphorylation at tyrosine 416 (activation). Administration of PP1, a highly selective Src inhibitor, blocked Src phosphorylation, improved renal function and ameliorated renal pathological damage. PP1 treatment also suppressed renal expression of neutrophil gelatinase-associated lipocalin and reduced apoptosis in the injured kidney. Moreover, Src inhibition prevented downregulation of several adherens and tight junction proteins, including E-cadherin, ZO-1, and claudins-1/-4 in the kidney after I/R injury as well as in cultured renal proximal tubular cells following oxidative stress. Finally, PP1 inhibited I/R-induced renal expression of matrix metalloproteinase-2 and -9, phosphorylation of extracellular signal-regulated kinases1/2, signal transducer and activator of transcription-3, and nuclear factor-κB, and the infiltration of macrophages into the kidney. These data indicate that Src is a pivotal mediator of renal epithelial injury and that its inhibition may have a therapeutic potential to treat AKI.

KEYWORDS:

E-cadherin; Src kinase; acute kidney injury; ischemia/reperfusion; metalloproteinase

PMID:
28415724
PMCID:
PMC5458204
DOI:
10.18632/oncotarget.16114
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center